Eledon Pharmaceuticals Inc expected to post a loss of 31 cents a share - Earnings Preview

Reuters11-06
Eledon Pharmaceuticals Inc <eldn.oq> expected to post a loss of 31 cents a share - Earnings Preview </eldn.oq>
  • Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected to show no change in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024

  • ​LSEG's mean analyst estimate for Eledon Pharmaceuticals Inc is for a loss of 31 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $10.00​, above​ its last closing price of $4.99. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Jun. 30 2024

-0.29

-0.30

-1.06

Missed

-249.4

Mar. 31 2024

-0.36

-0.37

-0.34

Beat

7

Dec. 31 2023

-0.39

-0.29

Beat

26​

Sep. 30 2023

-0.50

-0.46

-0.35

Beat

24

​​Jun. 30 2023

-0.46

-0.46

-0.40

Beat

12.8

Jan. 1 0001

-0.58

-0.60

-0.75

Missed

-25.2​

Jan. 1 0001

-0.78

-0.69

1.6

Sep. 30 2022

-0.68

-0.68

-0.73

Missed

-7.4

This summary was machine generated November 6 at 13:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment